Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News TCT 2020

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

L.A. McKeown

October 26, 2020

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

Todd Neale

September 25, 2019

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Presentation TCT 2012

Novel Anticoagulants in Patients with Acute Coronary Syndromes

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

The Potential of Otamixaban as a Procedural Anticoagulant

Presenter: Philippe Steg

October 24, 2012

Advertisement

Microclots Seen on OCT and Autopsy Can Inform COVID-19 Diagnostics, Care

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Strokes Increasing in STEMI Patients With Cardiogenic Shock

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Discussion Highlights Merits, Limitations of Small Trials

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Part 1: Oral Anticoagulants

Novel Anticoagulants in Patients with Acute Coronary Syndromes

The Potential of Otamixaban as a Procedural Anticoagulant

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content